The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader-Willi syndrome

Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes

“…[12][13][14][15] We also observed an increase in plasma ghrelin concentrations in the placebo group, consistent with a prolonged fast. 17 Ghrelin is known to stimulate lipolysis. An increase in ghrelin levels following liraglutide was reported previously in type 2 diabetes.…”

Mosapride citrate, a 5-HT₄ receptor agonist, increased the plasma active and total glucagon-like peptide-1 levels in non-diabetic men

“…Given the fact that diabetes develops when the insulin secretion by beta cells is insufficient to compensate for insulin resistance [22,23] and GLP-1 reportedly inhibits apoptosis in humans, the increase in the GLP-1 concentration may be important for improving beta cell function [24]. In addition, the increase in GLP-1 may protect against obesity because of the anti-obesity effect GLP-1 [25][26][27][28].…”

Glucagon like pepetide-1 agonist in a patient with prader-willi syndrome: a Sri Lankan experience

“…Similarly the drug was well tolerated in our patient as well. A Case reported from Japan of a patient with PWS on liraglutide therapy for one year duration, demonstrated suppression of appetite throughout the treatment duration and favorable reductions in body weight, visceral fat, HbA1c and Ghrelin levels (13). Fintinin et al reported improvement or stabilization of altered glucose metabolism and clinical parameters more evident during the first year of treatment in 6 patients with PWS who were treated with GLP-1 agonists for 2 years (14).…”